Dipyridamole Powder

Xi'an Faithful BioTech Co., Ltd: Your Trusted Dipyridamole Powder Manufacturer & Supplier

Dipyridamole Powder is a phosphodiesterase inhibitor that inhibits adenosine uptake and metabolism in red blood cells and vascular endothelial cells. Adenosine is an important vasoactive substance that can promote platelet aggregation. Therefore, the dipyridamole raw material provided by Xi'an Faithful BioTech Co., Ltd Company can inhibit platelet aggregation and blood coagulation, thereby achieving anticoagulant effects.

Dipyridamole Powder Introduction

Dipyridamole powder is a non nitrate coronary vasodilator that has the effects of dilating coronary arteries, promoting collateral circulation formation, and protecting endothelial cells. In addition, it can also inhibit platelet uptake of adenosine, thereby suppressing platelet aggregation and blood coagulation, achieving (anti aggregation) anticoagulant effect. In the early years, it was a commonly used medication for treating coronary heart disease, but now it is rarely used for anti myocardial ischemia. Its antiplatelet aggregation effect can be used in cardiac surgery or valve replacement surgery, which can reduce the formation of thromboembolism. Its side effects may include headaches, dizziness, nausea, vomiting, diarrhea, and other adverse reactions. When used in combination with Heparin powder, it can cause bleeding tendencies, occasional rash, and coronary artery steal.

Specifications

Why Choose Us? 

We chose our Dipyridamole API because we have an internationally certified quality system, advanced production processes, and strict quality control standards, which enable us to provide customers with high-quality and cost-effective API products. Our Dipyridamole raw material has passed international authoritative certifications such as FDA and EDQM. The product purity is ≥ 98.5%, the impurity content is strictly controlled within 1.0%, the single impurity is less than 0.5%, the biological activity is ≥ 80.0%, and the endotoxin is ≤ 50EU/mg. All quality indicators comply with international pharmacopoeia standards such as CP, USP, BP, EP, etc. Each batch of products provides a complete Certificate of Analysis (COA). We used solid-phase peptide synthesis technology and developed an efficient solid-phase synthesis process based on the Fmoc solid-phase synthesis principle. Microwave reaction technology was used to achieve a crude yield of up to 85% and a pure yield of 60% for Dipyridamole. During the synthesis process, the TBTU/HOBt/DIEA system was used as a condensing reagent. At peptide positions where alpha helices and beta angles are easily formed, HOBt/DIC was added to promote complete coupling reaction and ensure product purity of over 99.5%. With our large-scale production capacity and process optimization, our product prices are competitive in the market. At the same time, we provide comprehensive technical support services and stable supply guarantees to ensure customers have long-term stable partnerships. We can provide customized solutions according to customer needs to meet the production needs of different formulations.
please leave a message via email: sales8@faithfulbio.com ,Welcome to the store for inquiries.

Optimized English Version:​

API Dipyridamole has been reported in the literature to reduce proteinuria alongside its established antiplatelet activity, though high‑quality prospective studies are still needed to confirm this effect.

The potential mechanism by which dipyridamole reduces proteinuria may be as follows: Platelets can act through the platelet‑complement‑immune complex system, releasing chemical mediators that contribute to immune complex deposition and the development of proteinuria. Similar to Indometacin and acetylsalicylic acid, Dypyridamole shares several pharmacological properties, including a rapid onset of potent antiplatelet action. A key common feature is the inhibition of platelet aggregation and the suppression of platelet‑derived chemical mediator release induced by collagen, immune complexes, and other stimuli. Therefore, the proteinuria‑lowering effect of our dipyridamole powder is also likely achieved by blocking platelet aggregation and thereby preventing the release of vasoactive amines.

Experimental evidence indicates that platelets serve as storage cells for histamine and serotonin, and that their aggregation or adhesion to injured endothelial surfaces—triggered by immune complexes or collagen—can lead to the release of chemical mediators. This process promotes immune complex deposition, increases glomerular basement membrane permeability, and facilitates the development of glomerulonephritis, which in turn results in proteinuria. An appropriate dose of active Dypyridamole POWDER appears to interrupt this cascade. Human platelets are known to contain serotonin and other chemical mediators, and because Dypyridamole has been shown in vitro to effectively inhibit their release, a similar mechanism is presumed to operate in vivo. However, it remains plausible that the reduction in proteinuria may also involve other complex mechanisms related to its antiplatelet aggregation activity.

Quality Control:

Packaging and Transportation:

After-Sales Service: 

Qualification Certification:

Transaction Feedback: 

Exhibition: 

Contact us

Dipyridamole powder is mainly used for the secondary prevention of thromboembolic diseases and ischemic heart disease, especially for the prevention of stroke recurrence risk. In addition, it is also used for antithrombotic therapy after heart valve replacement surgery, Kawasaki disease (coronary artery protection in children), and prevention of microthrombi in chronic kidney disease. If you have relevant research, please leave a message, please leave a message:sales8@faithfulbio.com.